Pharma Reaserch Prod Co Ltd Market Cap ($1.55 Billion)
Market Cap & Net Worth: Pharma Reaserch Prod Co Ltd (214450)
Pharma Reaserch Prod Co Ltd market cap. Pharma Reaserch Prod Co Ltd (KQ:214450) has a market capitalization of $1.55 Billion (₩2.29 Trillion) as of November 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #6828 globally and #156 in its home market, demonstrating a -4.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pharma Reaserch Prod Co Ltd's stock price ₩220000.00 by its total outstanding shares 10389648 (10.39 Million). Also see 214450 operating cash flow for how efficiently the company converts equity into cash flow.
Pharma Reaserch Prod Co Ltd Market Cap History (2015–2026)
Pharma Reaserch Prod Co Ltd market cap history from 2015 to 2026. Data shows growth from $483.09 Million to $1.55 Billion (12.39% CAGR). Check Pharma Reaserch Prod Co Ltd stock price for real-time trading data and today's change.
Index Memberships
Pharma Reaserch Prod Co Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$203.83 Billion | 0.76% | #16 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$203.83 Billion | 0.76% | #16 of 1384 |
Weight: Pharma Reaserch Prod Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pharma Reaserch Prod Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pharma Reaserch Prod Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Pharma Reaserch Prod Co Ltd (214450) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.01x
Pharma Reaserch Prod Co Ltd's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.02x
Pharma Reaserch Prod Co Ltd's market cap is 0.02 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $269.40 Million | $45.95 Billion | $13.91 Billion | 0.01x | 0.02x |
| 2017 | $394.80 Million | $54.47 Billion | $12.96 Billion | 0.01x | 0.03x |
| 2018 | $227.68 Million | $64.28 Billion | $14.41 Billion | 0.00x | 0.02x |
| 2019 | $248.37 Million | $83.87 Billion | $16.67 Billion | 0.00x | 0.01x |
| 2020 | $393.67 Million | $108.75 Billion | $32.77 Billion | 0.00x | 0.01x |
| 2021 | $568.43 Million | $154.08 Billion | $46.69 Billion | 0.00x | 0.01x |
| 2022 | $489.16 Million | $194.76 Billion | $40.58 Billion | 0.00x | 0.01x |
| 2023 | $770.98 Million | $261.01 Billion | $76.55 Billion | 0.00x | 0.01x |
| 2024 | $1.85 Billion | $350.12 Billion | $92.04 Billion | 0.01x | 0.02x |
| 2025 | $2.84 Billion | $536.29 Billion | $165.12 Billion | 0.01x | 0.02x |
Competitor Companies of 214450 by Market Capitalization
Companies near Pharma Reaserch Prod Co Ltd in the global market cap rankings as of November 4, 2026. Also see 214450 asset base for a full breakdown of the balance sheet.
Key companies related to Pharma Reaserch Prod Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Pharma Reaserch Prod Co Ltd (2015–2026)
Market capitalization of Pharma Reaserch Prod Co Ltd from 2015 to today. Between 2015 and today, Pharma Reaserch Prod Co Ltd's market cap moved from $483.09 Million to $ 1.55 Billion, with a yearly change of 12.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩1.55 Billion | -45.41% |
| 2025 | ₩2.84 Billion | +53.52% |
| 2024 | ₩1.85 Billion | +139.73% |
| 2023 | ₩770.98 Million | +57.61% |
| 2022 | ₩489.16 Million | -13.95% |
| 2021 | ₩568.43 Million | +44.39% |
| 2020 | ₩393.67 Million | +58.50% |
| 2019 | ₩248.37 Million | +9.09% |
| 2018 | ₩227.68 Million | -42.33% |
| 2017 | ₩394.80 Million | +46.55% |
| 2016 | ₩269.40 Million | -44.24% |
| 2015 | ₩483.09 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Pharma Reaserch Prod Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.55 Billion USD |
| MoneyControl | $1.55 Billion USD |
| MarketWatch | $1.55 Billion USD |
| marketcap.company | $1.55 Billion USD |
| Reuters | $1.55 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pharma Reaserch Prod Co Ltd
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly… Read more